Trial
NCT03387514
Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Wisconsin, Madison
Collaborators
National Institutes of Health (NIH); National Cancer Institute (NCI)
Condition
Renal Cell Carcinoma
Intervention
PSMA-based 18F-DCFPyL PET tracer for PET/CT exams
Why stopped
Termination of funding due to low subject enrollment due to change in standard of care systemic therapy which limited available patients treated with anti-angiogenesis or combined immune and anti-angiogenesis therapy for enrollment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-12-21